In a report released today, Les Sulewski from Truist Financial assigned a Buy rating to biote (BTMD – Research Report), with a price target of $5.59. The company’s shares closed yesterday at $5.59.
According to TipRanks, Sulewski is a 4-star analyst with an average return of 19.1% and a 76.92% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, biote, and Cormedix.
Currently, the analyst consensus on biote is a Strong Buy with an average price target of $7.46, which is a 33.45% upside from current levels. In a report released on February 22, Jefferies also maintained a Buy rating on the stock with a $7.72 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $8.22 and a one-year low of $3.65. Currently, biote has an average volume of 102.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
biote (BTMD) Company Description:
Haymaker Acquisition Corp III is a blank check company.
Read More on BTMD:
- 3 Best Stocks to Buy Now, 2/22/2024, According to Top Analysts
- Biote Corp. Settles Litigation and Repurchases Founder’s Shares
- B. Riley starts Biote with Buy on horome replacement therapy potential
- Biote initiated with a Buy at B. Riley
- Biote initiated with a Buy at Jefferies with ‘platform revving up’
